[1] Zeng K,Wang Z,Ohshima K,et al.BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis[J].Oncoimmunology,2016,5(7):e1185582.
[2] Karimzada MM,Matthews MN,French SW,et al.Langerhans cell histiocytosis masquerading as acute appendicitis:Case report and review[J].World J Gastrointest Endosc,2017,9(3):139-144.
[3] Heritier S,Emile JF,Barkaoui MA,et al.A multicentre retrospective survey of Langerhans′ cell histiocytosis:348 cases observed between 1983 and 1993.The French Langerhans′ Cell Histiocytosis Study Group[J].Arch Dis Child,1996,75(1):17-24.
[4] Krooks J,Minkov M,Weatherall AG.Langerhans cell histiocytosis in children:History,classification,pathobiology,clinicalmanifestations,and prognosis[J].J Am Acad Dermatol 2018,78(6):1035-1044.
[5]Yadav SP, Kharya G,Mohan N,et al.Langerhans cell histiocytosis with digestive tract involvement[J].Pediatr Blood Cancer,2010,55(4):748-753.
[6] Shima H,Takahashi T,Shimada H.Protein-losing enteropathy caused by gastrointestinal tract-involved Langerhans cell histiocytosis[J].Pediatrics,2010,125 (2):e426-432.
[7] Zenga K,Wanga Z,Ohshimab K,et al.BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis[J].Onco Immunology,2016,5(7):e1185582.
[8] 吴升华.郎格罕细胞组织细胞增生症评估与治疗指南介绍[J].中华儿科杂志,2012,50(2):155-158.
[9] Zei M,Meyers AB,Boyd KP.Langerhans cell histiocytosis of the digestive tract identified on an upper gastrointestinalexamination[J].Pediatr Radiol,2016,46(9):1341-1344.
[10] Milen Minkov.An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy[J].Expert Opin Pharmacother,2018,19(3):233-242.
[11] Heritier S,Emile JF,Barkaoui MA,et al.BRAF Mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy[J].J Clin Oncol,2016,34(25):3023-3030. |
